Implementation of a gene panel for the genetic diagnosis of primary ciliary dyskinesia

Author(s):  
Sandra Rovira Amigo ◽  
Noelia Baz Redon ◽  
Núria Camats Tarruella ◽  
Mónica Fernández Cancio ◽  
Ida Paramonov ◽  
...  

Author(s):  
Noelia Baz-Redón ◽  
Sandra Rovira-Amigo ◽  
Ida Paramonov ◽  
Silvia Castillo-Corullón ◽  
Maria Cols-Roig ◽  
...  


2018 ◽  
Vol 39 (5) ◽  
pp. 653-665 ◽  
Author(s):  
Tamara Paff ◽  
Irsan E. Kooi ◽  
Youssef Moutaouakil ◽  
Elise Riesebos ◽  
Erik A. Sistermans ◽  
...  


2021 ◽  
pp. 2002359
Author(s):  
Amelia Shoemark ◽  
Bruna Rubbo ◽  
Marie Legendre ◽  
Mahmood R. Fassad ◽  
Eric G. Haarman ◽  
...  

BackgroundPrimary ciliary dyskinesia (PCD) is a heterogeneous inherited disorder caused by mutations in approximately 50 cilia-related genes. PCD genotype-phenotype relationships have mostly arisen from small case series because existing statistical approaches to investigate relationships have been unsuitable for rare diseases.MethodsWe applied a topological data analysis (TDA) approach to investigate genotype-phenotype relationships in PCD. Data from separate training and validation cohorts included 396 genetically defined individuals carrying pathogenic variants in PCD genes. To develop the TDA models, twelve clinical and diagnostic variables were included. TDA-driven hypotheses were subsequently tested using traditional statistics.ResultsDisease severity at diagnosis measured by FEV1 z-score was (i) significantly worse in individuals with CCDC39 mutations compared to other gene mutations and (ii) better in those with DNAH11 mutations; the latter also reported less neonatal respiratory distress. Patients without neonatal respiratory distress had better preserved FEV1 at diagnosis. Individuals with DNAH5 mutations were phenotypically diverse. Cilia ultrastructure and beat pattern defects correlated closely to specific causative gene groups, confirming these tests can be used to support a genetic diagnosis.ConclusionsThis large scale multi-national study presents PCD as a syndrome with overlapping symptoms and variation in phenotype, according to genotype. TDA modelling confirmed genotype-phenotype relationships reported by smaller studies (e.g. FEV1 worse with CCDC39 mutations), and identified new relationships, including FEV1 preservation with DNAH11 mutations and diversity of severity with DNAH5 mutations.



2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Gabrielle Wheway ◽  
N. Simon Thomas ◽  
Mary Carroll ◽  
Janice Coles ◽  
Regan Doherty ◽  
...  

Abstract Background It is estimated that 1–13% of cases of bronchiectasis in adults globally are attributable to primary ciliary dyskinesia (PCD) but many adult patients with bronchiectasis have not been investigated for PCD. PCD is a disorder caused by mutations in genes required for motile cilium structure or function, resulting in impaired mucociliary clearance. Symptoms appear in infancy but diagnosis is often late or missed, often due to the lack of a “gold standard” diagnostic tool and non-specific symptoms. Mutations in > 50 genes account for around 70% of cases, with additional genes, and non-coding, synonymous, missense changes or structural variants (SVs) in known genes presumed to account for the missing heritability. Methods UK patients with no identified genetic confirmation for the cause of their PCD or bronchiectasis were eligible for whole genome sequencing (WGS) in the Genomics England Ltd 100,000 Genomes Project. 21 PCD probands and 52 non-cystic fibrosis (CF) bronchiectasis probands were recruited in Wessex Genome Medicine Centre (GMC). We carried out analysis of single nucleotide variants (SNVs) and SVs in all families recruited in Wessex GMC. Results 16/21 probands in the PCD cohort received confirmed (n = 9), probable (n = 4) or possible (n = 3) diagnosis from WGS, although 13/16 of these could have been picked up by current standard of care gene panel testing. In the other cases, SVs were identified which were missed by panel testing. We identified variants in novel PCD candidate genes (IFT140 and PLK4) in 2 probands in the PCD cohort. 3/52 probands in the non-CF bronchiectasis cohort received a confirmed (n = 2) or possible (n = 1) diagnosis of PCD. We identified variants in novel PCD candidate genes (CFAP53 and CEP164) in 2 further probands in the non-CF bronchiectasis cohort. Conclusions Genetic testing is an important component of diagnosing PCD, especially in cases of atypical disease history. WGS is effective in cases where prior gene panel testing has found no variants or only heterozygous variants. In these cases it may detect SVs and is a powerful tool for novel gene discovery.



2014 ◽  
Vol 23 (13) ◽  
pp. 3362-3374 ◽  
Author(s):  
Alexandros Onoufriadis ◽  
Amelia Shoemark ◽  
Miriam Schmidts ◽  
Mitali Patel ◽  
Gina Jimenez ◽  
...  


2020 ◽  
Vol 26 (8) ◽  
Author(s):  
Fatemeh Sakhaee ◽  
Farzam Vaziri ◽  
Golnaz Bahramali ◽  
Seyed Davar Siadat ◽  
Abolfazl Fateh


Sign in / Sign up

Export Citation Format

Share Document